Dysbiosis

Gut bacteria and the immune system: How aging changes the microbiome and can lead to ‘inflammaging’

Retrieved on: 
Wednesday, April 3, 2024

Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.

Key Points: 
  • Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.
  • However, as the composition of our gut microbiome changes with age, a low level of inflammation can become constant throughout the body.
  • Let’s take a closer look at the gut microbiome and how it changes with age.

Gut microbiome imbalances in older adults

  • In fact, compared to other parts of the body, the gut microbiome has the largest number of bacteria.
  • In a healthy gut microbiome, there are four dominant families (or phyla) of microorganisms, including Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
  • Firmicutes and Bacteroidetes make up around 80 to 90 per cent of the gut microbiota in the digestive tract.
  • Over time, the shortage of beneficial bacteria such as Firmicutes in older adults starts to compromise the integrity of their intestinal barrier, causing it to become leaky.

How inflammaging works

  • Inflammaging creates an environment that is prone to inflammation, which is caused and maintained by several factors.
  • These can include microorganism imbalances in the intestines (microbial dysbiosis), psychological stress, physical inactivity, poor nutrition and chronic infections.

Maintaining a healthy balance of gut microbiota

  • More specifically, probiotics help improve the function of the intestinal barrier and regulate immune responses by modifying the composition of the gut microbiome.
  • It is clear that the immune system has an intricate relationship with the gut microbiome.
  • A healthy and well-balanced gut microbiome will strengthen the intestinal barrier, which helps to reduce inflammation throughout the body and support the immune system.
  • To achieve this, it is important to maintain a healthy and well-balanced lifestyle as we grow older.


Narveen Jandu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

BIOHM Health Inc. Partners with Virginia Tech to Accelerate Bacterial and Fungal Microbiome-Based Product Development and Commercialization through A.I.

Retrieved on: 
Thursday, March 7, 2024

BIOHM's dataset, one of the largest in the world, combines bacterial and fungal genetic sequencing with over 50 metadata points.

Key Points: 
  • BIOHM's dataset, one of the largest in the world, combines bacterial and fungal genetic sequencing with over 50 metadata points.
  • This collaboration marks a significant step forward in the development and commercialization of condition specific dietary supplements based on a more complete understanding of the microbiome.
  • BIOHM Health Inc. is renowned for its groundbreaking work in microbiome research, leveraging its dataset to develop the next generation of targeted microbiome-based products.
  • The partnership between BIOHM Health Inc. and Virginia Tech represents a collaborative effort to push the boundaries of microbiome research and product development.

Journal of Pharmaceutical Analysis Articles Provide Novel Insights into Previously Unknown Disease Mechanisms

Retrieved on: 
Tuesday, February 27, 2024

XI'AN, China, Feb. 27, 2024 /PRNewswire/ -- DCM is the leading cause of heart failure in patients with chronic diabetes, with unclear mechanisms and limited treatments. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system. Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown. In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.

Key Points: 
  • Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown.
  • In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.
  • Their findings, available online on 17 August 2023, were published in Volume 13, Issue 12 of the journal in December 2023.
  • Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

PRODIGY BIOTECH ENTERS INTO A PARTNERSHIP AGREEMENT WITH LEADING CANCER CENTER TO ADVANCE PRODUCTS TO IMPROVE OUTCOMES IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Retrieved on: 
Tuesday, February 6, 2024

The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024.

Key Points: 
  • The accelerator program launch was announced at the MSK Life Sciences Innovation Summit in New York City on January 26, 2024.
  • Prodigy and Memorial Sloan Kettering Cancer Center (MSK) will co-develop a product targeting Enterococcus sp.
  • to treat microbial dysbiosis in patients undergoing allogenic hematopoietic stem cell transplantation.
  • February 6, 2024 – Prodigy and MSK have entered into a sponsored research agreement through the MSK Therapeutics Accelerator program to evaluate Prodigy’s product candidate for the improvement of outcomes in patients undergoing allogenic hematopoietic stem cell transplantation (allo-HCT).

Empress Announces Formation of World Leading Scientific Advisory Board

Retrieved on: 
Tuesday, January 23, 2024

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.
  • The SAB will work closely with the leadership at Empress Therapeutics to advance the company’s Chemilogics™ platform and pipeline of drug leads.
  • “We are honored to have these extraordinary scientific leaders join Empress in its mission to generate safe, effective medicines faster and more predictably,” said Jason Park, Ph.D., Co-Founder and CEO of Empress Therapeutics.
  • “Our Scientific Advisory Board provides invaluable expertise across multiple aspects of our Chemilogics™ platform, which uses AI to discover therapeutic chemistry encoded in genetic data.

Toluna Appoints Scott Axcell as Chief Marketing Officer

Retrieved on: 
Tuesday, January 16, 2024

Toluna , the leading global insights technology and panel provider, today announced the appointment of Scott Axcell as Chief Marketing Officer.

Key Points: 
  • Toluna , the leading global insights technology and panel provider, today announced the appointment of Scott Axcell as Chief Marketing Officer.
  • As part of his role, Scott will be responsible for the strategy, execution, and overall success of Toluna’s global marketing efforts, overseeing product marketing, brand, creative, growth marketing, and marketing operations.
  • View the full release here: https://www.businesswire.com/news/home/20240116969563/en/
    As Chief Marketing Officer, Scott Axcell will lead the strategy and execution of global marketing efforts to fuel brand growth.
  • “I’m thrilled to take on this role as Chief Marketing Officer and I look forward to collaborating with our talented leaders and marketing team across the globe to build on our momentum while expanding and elevating our brand.”

Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement

Retrieved on: 
Monday, December 11, 2023

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.

Key Points: 
  • Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.
  • View the full release here: https://www.businesswire.com/news/home/20231210383233/en/
    The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.
  • “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients.
  • PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Microbiome, Ferring Pharmaceuticals.

Kanvas Biosciences Acquires Federation Bio Assets to Scale the Discovery, Development and Manufacturing of Microbiome-Based Therapeutics

Retrieved on: 
Wednesday, October 11, 2023

The deal also expands the company’s leadership and West Coast presence with the addition of Lee Swem , formerly Federation Bio’s Chief Science Officer, who joined Kanvas Biosciences as Chief Development Officer.

Key Points: 
  • The deal also expands the company’s leadership and West Coast presence with the addition of Lee Swem , formerly Federation Bio’s Chief Science Officer, who joined Kanvas Biosciences as Chief Development Officer.
  • “Kanvas Biosciences is leading the way in understanding exactly how the microbiome benefits human health.
  • With novel spatial biology and manufacturing platforms, Kanvas Biosciences is creating a first-in-category company capable of leveraging complex microbial therapies with hundreds of members simultaneously.
  • With early pre-clinical data showing promising results, Kanvas Biosciences and MD Anderson will soon begin drug manufacturing.

LogiX Biosciences Founder Describes Mission to ‘Solve the Unsolvable’ in Preventing Cold and Flu

Retrieved on: 
Wednesday, August 23, 2023

Gavin Gear, the founder and CEO of Monterey, California based startup LogiX Biosciences , issued a statement this week that the company is making significant progress in the groundbreaking field of Nasal Immune Modulation.

Key Points: 
  • Gavin Gear, the founder and CEO of Monterey, California based startup LogiX Biosciences , issued a statement this week that the company is making significant progress in the groundbreaking field of Nasal Immune Modulation.
  • “We've uncovered some tremendous breakthroughs and are looking forward to unveiling a non-steroidal, natural immune modulation approach in the near future,” said Gear.
  • “We believe we can reshape disease prevention by enhancing the body's natural defenses, focusing on the nasal cavity.
  • This isn't just symptom treatment—it's a revolution in health.”
    “Our research has been incredibly revealing and promising,” added Gear.